197 Longitudinal tau PET and atrophy 43. Pontecorvo MJ, Devous Sr MD, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748-63. 44. Jack Jr CR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain. 2018;141:1517-28. 45. Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA neurology. 2022;79:149-58. 46. Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. Journal of Neuroscience. 2018;38:4482-9. 47. Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R, Initiative AsDN. Association of amyloid-β CSF/PET discordance and tau load 5 years later. Neurology. 2020;95:e2648-e57. 48. Hanyu H, Sato T, Hirao K, Kanetaka H, Iwamoto T, Koizumi K. The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer’s disease: a longitudinal SPECT study. Journal of the neurological sciences. 2010;290:96-101. 49. Leuzy A, Rodriguez-Vieitez E, Saint-Aubert L, Chiotis K, Almkvist O, Savitcheva I, et al. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14:652-63. 7
RkJQdWJsaXNoZXIy MjY0ODMw